Literature DB >> 14652639

Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies.

De-Hui W Ku1, Yale S Arkel, Michael P Paidas, Charles J Lockwood.   

Abstract

We studied 33 women during normal uneventful pregnancies and with no history of previous adverse pregnancy events for markers of activated coagulation and thrombin activity including prothrombin fragment 1.2(PF1.2), thrombin- antithrombin (TAT), and soluble fibrin polymer (SFP). In addition, we measured potential thrombin generation through the addition of thromboplastin to patient plasma in the presence of a thrombin-specific chromogenic substrate determined serially over a period of time--Endogenous Thrombin Potential assay (ETP). This assay was performed with plasma treated and untreated with activated protein C (APC). The fibrinolytic system was assessed by measurement of thrombin activatable fibrinolysis inhibitor (TAFI). These findings were correlated with the levels of pro-inflammatory cytokines, interleukine-1 beta and tumor necrosis factor-alpha. Our data supports previous reports that indicate that resistance to activated protein C and coagulation activation markers are commonly increased in the later 2/3rds of pregnancy. There are no differences in thrombin generation potential, as determined by the ETP assay without the addition of APC, in the three trimesters. However, the thrombin reserve (TR), the ETP result without APC divided by the ETP result with the addition of APC, is increased above the reference range in the 2nd and 3rd trimesters. Patients with increased TR and resistance to APC had increased levels of TNF-alpha. Increased proinflammatory cytokines are reportedly associated with changes in the APC system with a decrease in the ability to generate APC. A sub-group of pregnancies with APC resistance had increased levels of TNF-alpha and may be important in the risk for adverse pregnancy outcomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652639     DOI: 10.1160/TH03-02-0119

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  DIC in Pregnancy - Pathophysiology, Clinical Characteristics, Diagnostic Scores, and Treatments.

Authors:  Offer Erez; Maha Othman; Anat Rabinovich; Elad Leron; Francesca Gotsch; Jecko Thachil
Journal:  J Blood Med       Date:  2022-01-06

Review 2.  [Hemorrhaging during pregnancy].

Authors:  S Hofer; R Schreckenberger; B Heindl; K Görlinger; H Lier; H Maul; E Martin; M A Weigand
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

3.  Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.

Authors:  Patrizia Ferroni; Silvia Riondino; Ilaria Portarena; Vincenzo Formica; Francesca La Farina; Francesca Martini; Gioia Massimiani; Raffaele Palmirotta; Fiorella Guadagni; Mario Roselli
Journal:  Int J Colorectal Dis       Date:  2012-05-12       Impact factor: 2.571

4.  Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes.

Authors:  Salvatore Andrea Mastrolia; Moshe Mazor; Giuseppe Loverro; Vered Klaitman; Offer Erez
Journal:  PeerJ       Date:  2014-11-18       Impact factor: 2.984

5.  Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis.

Authors:  Zoltan Bajko; Anca Motataianu; Adina Stoian; Laura Barcutean; Sebastian Andone; Smaranda Maier; Iulia-Adela Drăghici; Andrada Cioban; Rodica Balasa
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

6.  Postpartum Cerebral Venous Thrombosis-A Single-Center Experience.

Authors:  Zoltan Bajko; Anca Motataianu; Adina Stoian; Laura Barcutean; Sebastian Andone; Smaranda Maier; Iulia-Adela Drăghici; Rodica Balasa
Journal:  Brain Sci       Date:  2021-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.